Monoamine oxidase A rather than monoamine oxidase B inhibition increases nicotine reinforcement in rats

European Journal of Neuroscience

Volumn 24, Issue 12, 2006, Pages 3532-3540

  Guillem, Karine ^a   Vouillac, Caroline ^a   Azar, Marc R ^b   Parsons, Loren H ^b   Koob, George F ^b   Cador, Martine ^a   Stinus, Luis ^a  

^a CNRS   (France)

^b SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

Fixed ratio; Novelty; Progressive ratio; Selective MAOI

Indexed keywords

AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME A; AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME B; CARBOLINE DERIVATIVE; CLORGYLINE; NICOTINE; SELEGILINE;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; ENZYME ANALYSIS; ENZYME INHIBITION; LOCOMOTION; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; RAT; REINFORCEMENT; SMOKING; TASK PERFORMANCE; TOBACCO DEPENDENCE;

ANALYSIS OF VARIANCE; ANIMALS; BEHAVIOR, ANIMAL; COTININE; DRUG INTERACTIONS; MALE; MONOAMINE OXIDASE; MONOAMINE OXIDASE INHIBITORS; MOTOR ACTIVITY; NICOTINE; NICOTINIC AGONISTS; RATS; RATS, WISTAR; REINFORCEMENT (PSYCHOLOGY); REINFORCEMENT SCHEDULE; SELF ADMINISTRATION; TIME FACTORS;

EID: 33845603635     PISSN: 0953816X     EISSN: 14609568     Source Type: Journal    
DOI: 10.1111/j.1460-9568.2006.05217.x     Document Type: Article

References (97)

1. Balfour, D.J. (2002) The neurobiology of tobacco dependence: a commentary. Respiration, 69, 7-11.
2. Balfour, D.J. & Fagerström, K.O. (1996) Pharmacology of nicotine and its therapeutic use in smoking cessation and neurodegenerative disorders. Pharmacol. Ther., 72, 51-81.
3. Balfour, D.J., Benwell, M.E., Graham, C.A. & Vale, A.L. (1986) Behavioural and adrenocortical responses to nicotine measured in rats with selective lesions of the 5-hydroxytryptaminergic fibres innervating the hippocampus. Br. J. Pharmacol., 89, 341-347.
4. Balfour, D.J., Wright, A.E., Benwell, M.E. & Birrell, C.E. (2000) The putative role of extra-synaptic mesolimbic dopamine in the neurobiology of nicotine dependence. Behav. Brain Res., 113, 73-83.
5. Benowitz, N.L., Jacob, P., Fong, I. & Gupta, S. (1994) Nicotine metabolic profile in man: comparison of cigarette smoking and transdermal nicotine. J. Pharmacol. Exp. Ther., 268, 296-303.
6. Berlin, I. & Anthenelli, R.M. (2001) Monoamine oxidases and tobacco smoking. Int. J. Neuropsychopharmacol., 4, 33-42.
7. Berlin, I., Said, S., Spreux-Varoquaux, O., Olivares, R., Launay, J.M. & Puech, A.J. (1995) Monoamine oxidase A and B activities in heavy smokers. Biol. Psychiat., 38, 756-761.
8. Berridge, K.C. & Robinson, T.E. (1998) What is the role of dopamine in reward: hedonic impact, reward learning, or incentive salience? Brain Res. Brain Res. Rev., 28, 309-369.
9. Breyer-Pfaff, U., Wiatr, G., Stevens, I., Gaertner, H.J., Mundle, G. & Mann, K. (1996) Elevated norharman plasma levels in alcoholic patients and controls resulting from tobacco smoking. Life Sci., 58, 1425-1432.
10. Caggiula, A.R., Donny, E.C., White, A.R., Chaudhri, N., Booth, S., Gharib, M.A., Hoffman, A., Perkins, K.A. & Sved, A.F. (2001) Cue dependency of nicotine self-administration and smoking. Pharmacol. Biochem. Behav., 70, 515-530.
11. Caggiula, A.R., Donny, E.C., Chaudhri, N., Perkins, K.A., Evans-Martin, F.F. & Sved, A.F. (2002) Importance of nonpharmacological factors in nicotine self-administration. Physiol. Behav., 77, 683-687.
12. Cappendijk, S.L., Fekkes, D., van Dalen, A. & Pepplinkhuizen, L. (2001) The acute effects of norharman on cocaine self-administration and sensorimotor function in male Wistar rats. Eur. Neuropsychopharmacol., 11, 233-239.
13. Carboni, E., Bortone, L., Giua, C. & Di Chiara, G. (2000) Dissociation of physical abstinence signs from changes in extracellular dopamine in the nucleus accumbens and in the prefrontal cortex of nicotine dependent rats. Drug Alcohol Depend., 58, 93-102.
14. Cases, O., Seif, I., Grimsby, J., Gaspar, P., Chen, K., Pournin, S., Muller, U., Aguet, M., Babinet, C. & Shih, J.C. (1995) Aggressive behavior and altered amounts of brain serotonin and norepinephrine in mice lacking MAOA. Science, 268, 1763-1766.
15. Cohen, C., Curet, O., Perrault, G. & Sanger, D.J. (1999) Reduction of oral ethanol self-administration in rats by monoamine oxidase inhibitors. Pharmacol. Biochem. Behav., 64, 535-539.
16. Corrigall, W.A. & Coen, K.M. (1989) Nicotine maintains robust self-administration in rats on a limited-access schedule. Psychopharmacology (Berl.), 99, 473-478.
17. Corrigall, W.A., Franklin, K.B., Coen, K.M. & Clarke, P.B. (1992) The mesolimbic dopaminergic system is implicated in the reinforcing effects of nicotine. Psychopharmacology (Berl.), 107, 285-289.
18. Curet, O., Damoiseau, G., Aubin, N., Sontag, N., Rovei, V. & Jarreau, F.X. (1996) Befloxatone, a new reversible and selective monoamine oxidase-A inhibitor. I. Biochemical profile. J. Pharmacol. Exp. Ther., 277, 253-264.
19. De Colibus, L., Li, M., Binda, C., Lustig, A., Edmondson, D.E. & Mattevi, A. (2005) Three-dimensional structure of human monoamine oxidase A (MAO A): relation to the structures of rat MAO A and human MAO B. Proc. Natl Acad. Sci. U.S.A., 102, 12 684-12 689.
20. Depoortere, R.Y., Li, D.H., Lane, J.D. & Emmett-Oglesby, M.W. (1993) Parameters of self-administration of cocaine in rats under a progressive-ratio schedule. Pharmacol. Biochem. Behav., 45, 539-548.
21. Di Chiara, G. (1998) A motivational learning hypothesis of the role of mesolimbic dopamine in compulsive drug use. J. Psychopharmacol., 12, 54-67.
22. Di Chiara, G. (2000) Role of dopamine in the behavioural actions of nicotine related to addiction. Eur. J. Pharmacol., 393, 295-314.
23. Donny, E.C., Caggiula, A.R., Knopf, S. & Brown, C. (1995) Nicotine selfadministration in rats. Psychopharmacology (Berl.), 122, 390-394.
24. Donny, E.C., Chaudhri, N., Caggiula, A.R., Evans-Martin, F.F., Booth, S., Gharib, M.A., Clements, L.A. & Sved, A.F. (2003) Operant responding for a visual reinforcer in rats is enhanced by noncontingent nicotine: implications for nicotine self-administration and reinforcement. Psychopharmacology (Berl.), 169, 68-76.
25. Fagervall, I. & Ross, S.B. (1986) A and B forms of monoamine oxidase within the monoaminergic neurons of the rat brain. J. Neurochem., 47, 569-576.
26. Fekkes, D. & Bode, W.T. (1993) Occurrence and partition of the beta-carboline norharman in rat organs. Life Sci., 52, 2045-2054.
27. Felner, A.E. & Waldmeier, P.C. (1979) Cumulative effects of irreversible MAO inhibitors in vivo. Biochem. Pharmacol., 28, 995-1002.
28. Finberg, J.P. & Youdim, M.B. (1985) Modification of blood pressure and nictitating membrane response to sympathetic amines by selective monoamine oxidase inhibitors, types A and B, in the cat. Br. J. Pharmacol., 85, 541-546.
29. Fowler, J.S., Volkow, N.D., Wang, G.J., Pappas, N., Logan, J., MacGregor, R., Alexoff, D., Shea, C., Schlyer, D., Wolf, A.P., Warner, D., Zezulkova, I. & Cilento, R. (1996a) Inhibition of monoamine oxidase B in the brains of smokers. Nature, 379, 733-736.
30. Fowler, J.S., Volkow, N.D., Wang, G.J., Pappas, N., Logan, J., Shea, C., Alexoff, D., MacGregor, R.R., Schlyer, D., Zezulkova, I. & Wolf, A.P. (1996b) Brain monoamine oxidase A inhibition in cigarette smokers. Proc. Natl Acad. Sci. U.S.A., 93, 14 065-14 069.
31. Fowler, J.S., Logan, J., Ding, Y.S., Franceschi, D., Wang, G.J., Volkow, N.D., Pappaq, N., Schlyer, D., Gatley, S.J., Alexoff, D., Felder, C., Biegon, A. & Zhu, W. (2001) Non-MAO A binding of clorgyline in white matter in human brain. J. Neurochem., 79, 1039-1046.
32. Fowler, J.S., Logan, J., Wang, G.J., Volkow, N.D., Telang, F., Zhu, W., Franceschi, D., Pappas, N., Ferrieri, R., Shea, C., Garza, V., Xu, Y., Schlyer, D., Gatley, S.J., Ding, Y.S., Alexoff, D., Warner, D., Netusil, N., Carter, P., Jayne, M., King, P. & Vaska, P. (2003) Low monoamine oxidase B in peripheral organs in smokers. Proc. Natl Acad. Sci. U.S.A., 100, 11 600-11 605.
33. Galeote, L., Kieffer, B.L., Maldonado, R. & Berrendero, F. (2006) Mu-opioid receptors are involved in the tolerance to nicotine antinociception. J. Neurochem., 97, 416-423.
34. Garcia-Sevilla, J.A., Escriba, P.V. & Guimon, J. (1999) Imidazoline receptors and human brain disorders. Ann. N.Y. Acad. Sci., 881, 392-409.
35. Garrett, M.C. & Soares-da-Silva, P. (1990) Role of type A and B monoamine oxidase on the formation of 3,4-dihydroxyphenylacetic acid (DOPAC) in tissues from the brain of rats. Neuropharmacology, 29, 875-879.
36. Gerlach, M., Youdim, M.B. & Riederer, P. (1996) Pharmacology of selegiline. Neurology, 47, 137-145.
37. Goldberg, S.R., Spealman, R.D. & Goldberg, D.M. (1981) Persistent behavior at high rates maintained by intravenous self-administration of nicotine. Science, 214, 573-575.
38. Goldberg, S.R., Yasar, S., Bergman, J. & Youdim, M.B. (1994) Introduction: examination of clinical and preclinical pharmacologic data relating to abuse liability of l-deprenyl (selegiline). Clin. Pharmacol. Ther., 56, 721-724.
39. Grasing, K. & He, S. (2005) Effects of high-dose selegiline on morphine reinforcement and precipitated withdrawal in dependent rats. Behav. Pharmacol., 16, 1-13.
40. Grimsby, J., Toth, M., Chen, K., Kumazawa, T., Klaidman, L., Adams, J.D., Karoum, F., Gal, J. & Shih, J.C. (1997) Increased stress response and beta-phenylethylamine in MAOB-deficient mice. Nat. Genet., 17, 206-210.
41. Guillem, K., Vouillac, C., Azar, M.R., Parsons, L.H., Koob, G.F., Cador, M. & Stinus, L. (2005) Monoamine oxidase inhibition dramatically increases the motivation to self-administer nicotine in rats. J. Neurosci., 25, 8593-8600.
42. Herraiz, T. & Chaparro, C. (2005) Human monoamine oxidase enzyme inhibition by coffee and beta-carbolines norharman and harman isolated from coffee. Life Sci., 78, 795-802.
43. Herraiz, T. & Chaparro, C. (2006) Analysis of monoamine oxidase enzymatic activity by reversed-phase high performance liquid chromatography and inhibition by beta-carboline alkaloids occurring in foods and plants. J. Chromatogr. A, 1120, 237-243.
44. Hudson, A.L., Gough, R., Tyacke, R., Lione, L., Lalies, M., Lewis, J., Husbands, S., Knight, P., Murray, F., Hutson, P. & Nutt, D.J. (1999) Novel selective compounds for the investigation of imidazoline receptors. Ann. N.Y. Acad. Sci., 881, 81-91.
45. Husbands, S.M., Glennon, R.A., Gorgerat, S., Gough, R., Tyacke, R., Crosby, J., Nutt, D.J., Lewis, J.W. & Hudson, A.L. (2001) Beta-carboline binding to imidazoline receptors. Drug Alcohol Depend., 64, 203-208.
46. Inoue, H., Castagnoli, K., Van Der Schyf, C., Mabic, S., Igarashi, K. & Castagnoli, N. Jr (1999) Species-dependent differences in monoamine oxidase A and B-catalyzed oxidation of various C4 substituted 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridinyl derivatives. J. Pharmacol. Exp. Ther., 291, 856-864.
47. Jaffe, J.H. & Kanzler, M. (1979) Smoking as an addictive disorder. In: Krasnegor, N.A. (Ed.), Cigarette Smoking as a Dependence Process, NIDA Research Monograph, Vol. 23. NIDA, Rockville, Maryland, pp. 4-23.
48. Johnson, A.G. (1968) Monoamine oxidase inhibitors. Br. Med. J., 12, 433.
49. Kalgutkar, A.S., Dalvie, D.K., Castagnoli, N. & Taylor, T.J. (2001) Interactions of nitrogen-containing xenobiotics with monoamine oxidase (MAO) isozymes A and B: SAR studies on MAO substrates and inhibitors. Chem. Res. Toxicol., 14, 1139-1162.
50. Kato, T., Dong, B., Ishii, K. & Kinemuchi, H. (1986) Brain dialysis: in vivo metabolism of dopamine and serotonin by monoamine oxidase A but not B in the striatum of unrestrained rats. J. Neurochem., 46, 1277-1282.
51. Kleven, M.S. & Woolverton, W.L. (1993) Effects of three monoamine uptake inhibitors on behavior maintained by cocaine or food presentation in rhesus monkeys. Drug Alcohol Depend., 31, 149-158.
52. Knoll, J. & Magyar, K. (1972) Some puzzling pharmacological effects of monoamine oxidase inhibitors. Adv. Biochem. Psychopharmacol., 5, 393-408.
53. Krueger, M.J., Mazouz, F., Ramsay, R.R., Milcent, R. & Singer, T.P. (1995) Dramatic species differences in the susceptibility of monoamine oxidase B to a group of powerful inhibitors. Biochem. Biophys. Res. Commun., 206, 556-562.
54. Kuhn-Velten, W.N. (1993) Norharman (beta-carboline) as a potent inhibitory ligand for steroidogenic cytochromes P450 (CYP11 and CYP17). Eur. J. Pharmacol., 250, R1-R3.
55. Kumagae, Y., Matsui, Y. & Iwata, N. (1991) Deamination of norepinephrine, dopamine, and serotonin by type A monoamine oxidase in discrete regions of the rat brain and inhibition by RS-8359. Jpn J. Pharmacol., 55, 121-128.
56. Lamensdorf, I., Youdim, M.B. & Finberg, J.P. (1996) Effect of long-term treatment with selective monoamine oxidase A and B inhibitors on dopamine release from rat striatum in vivo. J. Neurochem., 67, 1532-1539.
57. Lan, N.C., Chen, C.H. & Shih, J.C. (1989) Expression of functional human monoamine oxidase A and B cDNAs in mammalian cells. J. Neurochem., 52, 1652-1654.
58. Lee, M., Chen, K., Shih, J.C. & Hiroi, N. (2004) MAO-B knockout mice exhibit deficient habituation of locomotor activity but normal nicotine intake. Genes Brain Behav., 3, 216-227.
59. Lucas, G. & Spampinato, U. (2000) Role of striatal serotonin2A and serotonin2C receptor subtypes in the control of in vivo dopamine outflow in the rat striatum. J. Neurochem., 74, 693-701.
60. MacInnes, N. & Handley, S.L. (2002) Characterization of the discriminable stimulus produced by 2-BFI: effects of imidazoline I(2)-site ligands, MAOIs, beta-carbolines, agmatine and ibogaine. Br. J. Pharmacol., 135, 1227-1234.
61. Manzardo, A.M., Stein, L. & Belluzzi, J.D. (2002) Rats prefer cocaine over nicotine in a two-lever self-administration choice test. Brain Res., 924, 10-19.
62. May, T., Pawlik, M. & Rommelspacher, H. (1991) 3[H] harman binding experiments. II: Regional and subcellular distribution of specific [3H]harman binding and monoamine oxidase subtypes A and B activity in marmoset and rat. J. Neurochem., 56, 500-508.
63. Messina, E.S., Tyndale, R.F. & Sellers, E.M. (1997) A major role for CYP2A6 in nicotine C-oxidation by human liver microsomes. J. Pharmacol. Exp. Ther., 282, 1608-1614.
64. Miralles, A., Esteban, S., Sastre-Coll, A., Moranta, D., Asensio, V.J. & Garcia-Sevilla, J.A. (2005) High-affinity binding of beta-carbolines to imidazoline I2B receptors and MAO-A in rat tissues: norharman blocks the effect of morphine withdrawal on DOPA / noradrenaline synthesis in the brain. Eur. J. Pharmacol., 518, 234-242.
65. Mitchell, S.N. (1993) Role of the locus coeruleus in the noradrenergic response to a systemic administration of nicotine. Neuropharmacology, 32, 937-949.
66. Müller, W.E., Fehske, K.J., Borbe, H.O., Wollert, U., Nanz, C. & Rommelspacher, H. (1981) On the neuropharmacology of harmane and other beta-carbolines. Pharmacol. Biochem. Behav., 14, 693-699.
67. Nakajima, M., Yamamoto, T., Nunoya, K., Yokoi, T., Nagashima, K., Inoue, K., Funae, Y., Shimada, N., Kamataki, T. & Kuroiwa, Y. (1996) Characterization of CYP2A6 involved in 3′-hydroxylation of cotinine in human liver microsomes. J. Pharmacol. Exp. Ther., 277, 1010-1015.
68. Norman, T.R., Chamberlain, K.G. & French, M.A. (1987) Platelet monoamine oxidase: low activity in cigarette smokers. Psychiat. Res., 20, 199-205.
69. Olausson, P., Engel, J.A. & Soderpalm, B. (2002) Involvement of serotonin in nicotine dependence: processes relevant to positive and negative regulation of drug intake. Pharmacol. Biochem. Behav., 71, 757-771.
70. Oreland, L., Fowler, C.J. & Schalling, D. (1981) Low platelet monoamine oxidase activity in cigarette smokers. Life Sci., 29, 2511-2518.
71. Paterson, I.A., Juorio, A.V., Berry, M.D. & Zhu, M.Y. (1991) Inhibition of monoamine oxidase-B by (-)-deprenyl potentiates neuronal responses to dopamine agonists but does not inhibit dopamine catabolism in the rat striatum. J. Pharmacol. Exp. Ther., 258, 1019-1026.
72. Pierce, J.P. & Gilpin, E.A. (2002) Impact of over-the-counter sales on effectiveness of pharmaceutical aids for smoking cessation. JAMA, 288, 1260-1264.
73. Poindexter, E.H. & Carpenter, R.D. (1962) The isolation of harmane and norharmane from tobacco and cigarette smoke. Phytochemistry, 1, 215-221.
74. Pontieri, F.E., Tanda, G., Orzi, F. & Di Chiara, G. (1996) Effects of nicotine on the nucleus accumbens and similarity to those of addictive drugs. Nature, 382, 255-257.
75. Robinson, E.S., Anderson, N.J., Crosby, J., Nutt, D.J. & Hudson, A.L. (2003) Endogenous beta-carbolines as clonidine-displacing substances. Ann. N.Y. Acad. Sci., 1009, 157-166.
76. Rommelspacher, H., Meier-Henco, M., Smolka, M. & Kloft, C. (2002) The levels of norharman are high enough after smoking to affect monoamine oxidase B in platelets. Eur. J. Pharmacol., 441, 115-125.
77. Rose, J.E., Behm, F.M., Ramsey, C. & Ritchie, J.C. Jr (2001) Platelet monoamine oxidase, smoking cessation, and tobacco withdrawal symptoms. Nicotine Tob. Res., 3, 383-390.
78. Saura, J., Kettler, R., Da Prada, M. & Richards, J.G. (1992) Quantitative enzyme radioautography with 3H-Ro 41-1049 and 3H-Ro 19-6327 in vitro: localization and abundance of MAO-A and MAO-B in rat CNS, peripheral organs, and human brain. J. Neurosci., 12, 1977-1999.
79. Seth, P., Cheeta, S., Tucci, S. & File, S.E. (2002) Nicotinic-serotonergic interactions in brain and behaviour. Pharmacol. Biochem. Behav., 71, 795-805.
80. Shih, J.C., Chen, K. & Ridd, M.J. (1999) Role of MAO A and B in neurotransmitter metabolism and behavior. Pol. J. Pharmacol., 51, 25-29.
81. Shimazu, S., Minami, A., Kusumoto, H. & Yoneda, F. (2005) Antidepressant-like effects of selegiline in the forced swim test. Eur. Neuropsychopharmacol., 15, 563-571.
82. Stolerman, I.P. & Jarvis, M.J. (1995) The scientific case that nicotine is addictive. Psychopharmacology (Berl.), 117, 2-10.
83. Stolerman, I.P. & Shoaib, M. (1991) The neurobiology of tobacco addiction. Trends Pharmacol. Sci., 12, 467-473.
84. Tassin, J.P., Vezina, P., Trovero, F., Blanc, G., Herve, D. & Glowinski, J. (1992) Cortico-subcortical interactions in behavioral sensitization: differential effects of daily nicotine and morphine. Ann. N.Y. Acad. Sci., 654, 101-116.
85. Tella, S.R. (1995) Effects of monoamine reuptake inhibitors on cocaine self-administration in rats. Pharmacol. Biochem. Behav., 51, 687-692.
86. Todd, K.G. & Baker, G.B. (1995) GABA-elevating effects of the antidepressant/antipanic drug phenelzine in brain: effects of pretreatment with tranylcypromine, (-)-deprenyl and clorgyline. J. Affect. Disord., 35, 125-129.
87. Vezina, P., Blanc, G., Glowinski, J. & Tassin, J.P. (1992) Nicotine and morphine differentially activate brain dopamine in prefrontocortical and subcortical terminal fields: effects of acute and repeated injections. J. Pharmacol. Exp. Ther., 261, 484-490.
88. Villegier, A.S., Salomon, L., Granon, S., Changeux, J.P., Belluzzi, J.D., Leslie, F.M. & Tassin, J.P. (2005) Monoamine oxidase inhibitors allow locomotor and rewarding responses to nicotine. Neuropsychopharmacology, 31, 1704-1713.
89. Waldemeier, P.C., Lauber, J., Blum, W. & Richter, W.J. (1981) 3-Methoxytyramine: its suitability as an indicator of synaptic dopamine release. Naunyn Schmiedebergs Arch. Pharmacol., 315, 219-225.
90. Waldmeier, P.C. & Baumann, P.A. (1983) Effects of CGP 11305 A, a new reversible and selective inhibitor of MAO A, on biogenic amine levels and metabolism in the rat brain. Naunyn Schmiedebergs Arch. Pharmacol., 324, 20-26.
91. Walters, C.L., Cleck, J.N., Kuo, Y.C. & Blendy, J.A. (2005) Mu-opioid receptor and CREB activation are required for nicotine reward. Neuron, 46, 933-943.
92. Watkins, S.S., Stinus, L., Koob, G.F. & Markou, A. (2000) Reward and somatic changes during precipitated nicotine withdrawal in rats: centrally and peripherally mediated effects. J. Pharmacol. Exp. Ther., 292, 1053-1064.
93. Weyler, W., Hsu, Y.P. & Breakefield, X.O. (1990) Biochemistry and genetics of monoamine oxidase. Pharmacol. Ther., 47, 391-417.
94. Winger, G.D., Yasar, S., Negus, S.S. & Goldberg, S.R. (1994) Intravenous self-administration studies with l-deprenyl (selegiline) in monkeys. Clin. Pharmacol. Ther., 56, 774-780.
95. Yong, V.W. & Perry, T.L. (1986) Monoamine oxidase B, smoking, and Parkinson's disease. J. Neurol. Sci., 72, 265-272.
96. Zhang, W., Kilicarslan, T., Tyndale, R.F. & Sellers, E.M. (2001) Evaluation of methoxsalen, tranylcypromine, and tryptamine as specific and selective CYP2A6 inhibitors in vitro. Drug Metab. Dispos., 29, 897-902.
97. Zhang, L., Kendler, K.S. & Chen, X. (2006) The mu-opioid receptor gene and smoking initiation and nicotine dependence. Behav. Brain Funct., 2, 28.